Percutaneous Coronary Intervention in Acute Coronary Syndrome with Mild-to-Moderate Thrombocytopenia
Yicong Ye,Yongchen Hao,Xiliang Zhao,Jun Liu,Na Yang,Sidney C. Smith,Yong Huo,Gregg C. Fonarow,Junbo Ge,Louise Morgan,Zhaoqing Sun,Danqing Hu,Yiqian Yang,Chang-Sheng Ma,Dong Zhao,Yaling Han,Jing Liu,Yong Zeng
DOI: https://doi.org/10.1055/a-2225-5263
2024-01-12
Thrombosis and Haemostasis
Abstract:Background Baseline thrombocytopenia is commonly observed in patients with acute coronary syndrome (ACS) requiring percutaneous coronary intervention (PCI). Aim The purpose of this analysis was to investigate safety and effectiveness of PCI in ACS patients with baseline mild-to-moderate thrombocytopenia. Methods The data were collected from the Improving Care for Cardiovascular Disease in China–Acute Coronary Syndrome project. A total of 50,009 ACS patients were recruited between July 2017 and December 2019. Among them, there were 6,413 patients with mild-to-moderate thrombocytopenia, defined as a platelet count of ≥50 × 10 9 /L and <150 × 10 9 /L on admission. The primary outcome was in-hospital net adverse clinical events (NACE), consisting of major adverse cardiac events (MACE) and major bleeding events. The associations between PCI and in-hospital outcomes were analyzed by inverse probability treatment weighting (IPTW) method. Results PCI was performed in 4,023 of 6,413 patients (62.7%). The IPTW analysis showed that PCI was significantly associated with a reduced risk of in-hospital MACE (odd ratio [OR]: 0.45; 95% confidence interval [CI]: 0.31–0.67; p < 0.01) and NACE (OR: 0.59; 95% CI: 0.42–0.83; p < 0.01). PCI was also associated with an increased risk of any bleeding (OR: 1.56; 95% CI: 1.09–2.22; p = 0.01) and minor bleeding (OR: 1.52; 95% CI: 1.00–2.30; p = 0.05), but not major bleeding (OR: 1.51; 95% CI: 0.76–2.98; p = 0.24). Conclusion Compared with medical therapy alone, PCI is associated with better in-hospital outcomes in ACS patients with mild-to-moderate thrombocytopenia. Further studies with long-term prognosis are needed. The present study was registered at URL: https://www.clinicaltrials.gov (Unique identifier: NCT02306616), approved by the Ethics Committee of the Beijing Anzhen Hospital, Capital Medical University with a waiver for informed consent, and performed in compliance with the Declaration of Helsinki. All methods were performed in accordance with relevant guidelines and regulations. The datasets generated and/or analyzed during the current study are not publicly available due to the decision of the study committee, but are available from the corresponding author on reasonable request. Y.H. and Y.Z. conceived of the study, designed the study, and revised the paper. Y.Y. and Y.H. performed the research, analyzed data, and wrote the paper. The remaining authors contributed to refining the ideas and finalizing this paper. All authors read and approved the final manuscript. * These authors contributed equally to the study. Received: 24 April 2023 Accepted: 08 December 2023 Accepted Manuscript online: 11 December 2023 Article published online: 10 January 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
peripheral vascular disease,hematology